symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
LUMO,4.18,0.528748,17965,33170139,0,2.63-9.21,-0.09,"Lumos Pharma, Inc.",USD,0001126234,US55028X1090,55028X109,NASDAQ Global Market,NASDAQ,Biotechnology,https://www.lumos-pharma.com,"Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.",Mr. Richard J. Hawkins,Healthcare,US,32,512 215 2630,4200 Marathon Boulevard,Austin,TX,78756,12.7577,16.2077,https://financialmodelingprep.com/image-stock/LUMO.png,2011-11-11,False,False,True,False,False
